Patents by Inventor Richard Gibson

Richard Gibson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12312946
    Abstract: A method can be used to determine multi-phase measurements of fluid flowing with respect to a wellbore. Signals can be received, and the signals can be emitted by each variable frequency acoustic emitter of a set of variable frequency acoustic emitters positioned spaced apart in a sensing transducer that is in an interior of a wellbore. The received signals can be converted into a flow rate of each of a set of different fluid phases of a fluid in the wellbore. The multi-phase measurements of the fluid can be determined using the converted flow rate.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: May 27, 2025
    Assignee: Halliburton Energy Services, Inc.
    Inventors: Julian Drew, David Diller, Werner Heigl, Richard Gibson, Jr., Barry Fish
  • Publication number: 20250102357
    Abstract: Tunable or swept cat's-eye lasers for spectroscopy that is adapted for direct mounting to a flow cell and/or includes an internal gas cell and is appropriate for installation in adverse environments and capable of automated alignment and installation in explosion proof enclosures.
    Type: Application
    Filed: September 25, 2024
    Publication date: March 27, 2025
    Inventors: Walid A. Atia, Richard Gibson-Dee
  • Patent number: 11993595
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.
    Type: Grant
    Filed: September 1, 2022
    Date of Patent: May 28, 2024
    Assignee: Mission Therapeutics Limited
    Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Karl Richard Gibson, Gavin Alistair Whitlock, Andrew Madin
  • Patent number: 11970939
    Abstract: Aspects of the subject technology relate to systems, methods, and computer-readable media for machine learning analysis of low-frequency signal data in fracturing operations. The present technology can receive strain data associated with a monitoring well that is proximate to a treatment well. The strain data can comprise information representing a fracturing operation associated with the treatment well. Further, the present technology can convert the strain data into image data where a color scale corresponds to a degree of strain observed by a fiber optic cable deployed in the monitoring well. As follows, the present technology can provide the image data to a machine-learning model, which is configured to identify one or more features in the image data.
    Type: Grant
    Filed: July 15, 2022
    Date of Patent: April 30, 2024
    Assignee: HALLIBURTON ENERGY SERVICES, INC.
    Inventors: Benjamin Schaeffer, Mikko K. Jaaskelainen, Richard Gibson
  • Publication number: 20240018866
    Abstract: Aspects of the subject technology relate to systems, methods, and computer-readable media for machine learning analysis of low-frequency signal data in fracturing operations. The present technology can receive strain data associated with a monitoring well that is proximate to a treatment well. The strain data can comprise information representing a fracturing operation associated with the treatment well. Further, the present technology can convert the strain data into image data where a color scale corresponds to a degree of strain observed by a fiber optic cable deployed in the monitoring well. As follows, the present technology can provide the image data to a machine-learning model, which is configured to identify one or more features in the image data.
    Type: Application
    Filed: July 15, 2022
    Publication date: January 18, 2024
    Applicant: Halliburton Energy Services, Inc.
    Inventors: Benjamin SCHAEFFER, Mikko K. JAASKELAINEN, Richard GIBSON
  • Publication number: 20230316815
    Abstract: A system may include a processor to receive vehicle data from a vehicle system at a first location and communicate the data to a second location. The processor may integrate the data into a database of diagnostic data at the second location and identify a diagnostic code that indicates an expected operation of the vehicle system or an unexpected operation. The processor may determine a maintenance operation based on the diagnostic code. A method may include receiving vehicle data from a vehicle system at a first location and communicating the vehicle data to a second location. The method may include integrating the vehicle data into a database of first diagnostic data and identifying a diagnostic code that indicates whether the vehicle data represents an expected operation of the vehicle system or an unexpected operation of the vehicle system. The method may include determining a maintenance operation based on the code.
    Type: Application
    Filed: March 31, 2022
    Publication date: October 5, 2023
    Inventors: Nicholas Roddy, Umang Gopalbhai Brahmakshatriya, Hammad Shaikh, Yoshita Jain, John Lahut, Benedict Lander, David Richard Gibson, Bernhard J. Scholz, David Joseph Schroeck, Jason Quigley
  • Patent number: 11660293
    Abstract: There is provided a compound of formula (I), wherein L1 to L3?, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: May 30, 2023
    Assignee: CHRONOS THERAPEUTICS LIMITED
    Inventors: Fabrizio Micheli, Barbara Bertani, Karl Richard Gibson, Romano Di Fabio, Luca Raveglia, Riccardo Zanaletti, Susanna Cremonesi, Alfonso Pozzan, Teresa Semeraro, Luca Tarsi, Timothy Jon Luker
  • Publication number: 20230144034
    Abstract: A method can be used to determine multi-phase measurements of fluid flowing with respect to a wellbore. Signals can be received, and the signals can be emitted by each variable frequency acoustic emitter of a set of variable frequency acoustic emitters positioned spaced apart in a sensing transducer that is in an interior of a wellbore. The received signals can be converted into a flow rate of each of a set of different fluid phases of a fluid in the wellbore. The multi-phase measurements of the fluid can be determined using the converted flow rate.
    Type: Application
    Filed: June 3, 2022
    Publication date: May 11, 2023
    Inventors: Julian Drew, David Diller, Werner Heigl, Richard Gibson, JR., Barry Fish
  • Publication number: 20230052191
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.
    Type: Application
    Filed: September 1, 2022
    Publication date: February 16, 2023
    Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Karl Richard Gibson, Gavin Alistair Whitlock, Andrew Madin
  • Publication number: 20230036854
    Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein R1, R2, R4, R5, R6, R7, R8, R9, R10, Z, X1, X2, X3, L2, HET, n and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.
    Type: Application
    Filed: November 15, 2019
    Publication date: February 2, 2023
    Inventors: Gareth RICHARDS, Timothy M. SKERRY, Joseph P.A. HARRITY, Jean-Olivier ZIRIMWABAGABO, Matthew J. TOZER, Karl Richard GIBSON, Roderick Alan PORTER, Paul Alan GLOSSOP
  • Publication number: 20220331299
    Abstract: There is provided a compound of formula (I), wherein L1 to L3?, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.
    Type: Application
    Filed: August 31, 2018
    Publication date: October 20, 2022
    Inventors: Fabrizio Micheli, Barbara Bertani, Karl Richard Gibson, Romano Di Fabio, Luca Raveglia, Riccardo Zanaletti, Susanna Cremonesi, Alfonso Pozzan, Teresa Semeraro, Luca Tarsi, Timothy Jon Luker
  • Patent number: 11472798
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: October 18, 2022
    Assignee: MISSION THERAPEUTICS LTD
    Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Karl Richard Gibson, Gavin Alistair Whitlock, Andrew Madin
  • Patent number: 11400081
    Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: August 2, 2022
    Assignee: The University of Sheffield
    Inventors: Gareth Richards, Timothy M. Skerry, Joseph P. A. Harrity, Jean-Olivier Zirimwabagabo, Matthew J. Tozer, Karl Richard Gibson, Roderick Alan Porter, Paul Matthew Blaney, Paul Alan Glossop
  • Publication number: 20220169653
    Abstract: The present invention relates to pyrrolopyrimidine compounds according to Formula I and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. In a particular aspect, the present compounds are ASK inhibitors, particularly ASK1 inhibitors. The present invention also provides methods for the production of a compound of the invention, pharmaceutical compositions comprising a compound of the invention, the use of the compounds in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases.
    Type: Application
    Filed: September 3, 2021
    Publication date: June 2, 2022
    Inventors: David AMANTINI, Milan MESIC, Gordon SAXTY, Tanja POLJAK, Ines VUJASINOVIC, Dinko ZIHER, David WITTY, Karl Richard GIBSON
  • Publication number: 20220023281
    Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein HET, R1, R2, R3, R4, R5, L, L1, X1, X2, X3 and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.
    Type: Application
    Filed: November 15, 2019
    Publication date: January 27, 2022
    Inventors: Gareth RICHARDS, Timothy M. SKERRY, Joseph P.A. HARRITY, Jean-Olivier ZIRIMWABAGABO, Matthew J. TOZER, Karl Richard GIBSON, Roderick Alan PORTER, Paul Alan GLOSSOP
  • Patent number: 11136325
    Abstract: The present invention relates to pyrrolopyrimidine compounds according to Formula I and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. In a particular aspect, the present compounds are ASK inhibitors, particularly ASK1 inhibitors. The present invention also provides methods for the production of a compound of the invention, pharmaceutical compositions comprising a compound of the invention, the use of the compounds in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: October 5, 2021
    Assignee: GALAPAGOS NV
    Inventors: David Amantini, Milan Mesic, Gordon Saxty, Tanja Poljak, Ines Vujasinovic, Dinko Ziher, David Witty, Karl Richard Gibson
  • Patent number: 11025553
    Abstract: Conventional internet routing is handled using routing protocols such as the Border Gateway Protocol (BGP). However, simple BGP does not account for latency, packet loss, or cost. To address this problem, smart routing systems that route traffic fast and in a cost-effective manner are implemented. In one approach, smart routing systems measure, compare, and analyze round-trip latencies and other metrics between a customer premises and one or more endpoints. Optimal inbound and outbound transit providers are selected for each endpoint based on these measurements. Other smart routing systems collect and analyze Real User Monitoring (RUM) data to predict latency performance of different content origins for serving data to a particular client based on the client's IP address and the content origins' IP addresses, which are ranked by performance.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: June 1, 2021
    Assignee: Dynamic Network Services, Inc.
    Inventors: Alin Popescu, Philip Stanhope, Arun Mehra, Stephen Hulshof, Brian Premore, Douglas Madory, Scott Michael Brazina, Charlie Baker, Richard Gibson
  • Publication number: 20210113534
    Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.
    Type: Application
    Filed: May 16, 2018
    Publication date: April 22, 2021
    Inventors: Gareth Richards, Timothy M. Skerry, Joseph P.A. Harrity, Jean-Olivier Zirimwabagabo, Matthew J. Tozer, Karl Richard Gibson, Roderick Alan Porter, Paul Matthew Blaney, Paul Alan Glossop
  • Publication number: 20200369658
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.
    Type: Application
    Filed: August 11, 2020
    Publication date: November 26, 2020
    Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Karl Richard Gibson, Gavin Alistair Whitlock, Andrew Madin
  • Patent number: 10774078
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: September 15, 2020
    Assignee: MISSION THERAPEUTICS LTD
    Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Karl Richard Gibson, Gavin Alistair Whitlock, Andrew Madin